HU6 not checked

Rivus Pharmaceuticals, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
11 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“HU6 is being evaluated for its efficacy in improving liver fat content in subjects with Nonalcoholic Steatohepatitis (NASH)”In the company’s words, NCT05979779 on ClinicalTrials.gov
Tested for
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Main trialPhase 2
“This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepatitis (NASH). Six months (26 weeks) of dosing is planned, and subjects will be followed for safety, efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) during this time. The end-of-study visit will take place approximately 4 weeks after the last dose of the study drug (Week 30).”In the company’s words, NCT05979779 on ClinicalTrials.gov

Other drugs for Non-Alcoholic Fatty Liver Disease

All 30 drugs for Non-Alcoholic Fatty Liver Disease

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 21 Jan 2025 Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
Phase 2Recruiting Feb 2027 A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
Phase 2Completed 30 Nov 2021 Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
Phase 2Completed 24 May 2024 Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
Phase 2Withdrawn Feb 2025 Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes
Phase 1Completed 30 Mar 2021 Ascending Dose Study of HU6 in Healthy Volunteers
Phase 1Completed 30 Apr 2021 Multiple Ascending Dose Study of HU6 in High BMI Volunteers
Phase 1Completed 30 Jan 2023 Safety and Pharmacokinetics of HU6
Phase 1Completed 7 May 2024 A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6
Phase 1Completed 15 Nov 2024 Relative Bioavailability Study of HU6
Phase 1Completed 4 Dec 2025 Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow HU6

Following is part of Solo: you see every change to HU6 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in